Evaluating the Diagnostic Accuracy of Heat Shock Proteins and Their Combination with Alpha-Fetoprotein in the Detection of Hepatocellular Carcinoma: a Meta-analysis

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2024 May 21

PMID 38773451

Authors

Dan Xiang

Lifang Fu

Ying Yang

Chengjiang Liu

Yong He

Affiliations

Soon will be listed here.

Abstract

Background: A growing body of research suggests that heat shock proteins (HSPs) may serve as diagnostic biomarkers for hepatocellular carcinoma (HCC), but their results are still controversial. This meta-analysis endeavors to evaluate the diagnostic accuracy of HSPs both independently and in conjunction with alpha-fetoprotein (AFP) as novel biomarkers for HCC detection.

Methods: Pooled statistical indices, including sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) with 95% confidence intervals (CI), were computed to assess the diagnostic accuracy of HSPs, AFP, and their combinations. Additionally, the area under the summary receiver operating characteristic (SROC) curve (AUC) was determined.

Results: A total of 2013 HCC patients and 1031 control subjects from nine studies were included in this meta-analysis. The summary estimates for HSPs and AFP are as follows: sensitivity of 0.78 (95% CI: 0.69-0.85) compared to 0.73 (95% CI: 0.65-0.80); specificity of 0.89 (95% CI: 0.81-0.95) compared to 0.86 (95% CI: 0.77-0.91); PLR of 7.4 (95% CI: 3.7-14.9) compared to 5.1 (95% CI: 3.3-8.1); NLR of 0.24 (95% CI: 0.16-0.37) compared to 0.31 (95% CI: 0.24-0.41); DOR of 30.19 (95% CI: 10.68-85.37) compared to 16.34 (95% CI: 9.69-27.56); and AUC of 0.90 (95% CI: 0.87-0.92) compared to 0.85 (95% CI: 0.82-0.88). The pooled sensitivity, specificity, PLR, NLR, DOR and AUC were 0.90 (95% CI: 0.82-0.95), 0.94 (95% CI: 0.82-0.98), 14.5 (95% CI: 4.6-45.4), 0.11 (95% CI: 0.06-0.20), 133.34 (95% CI: 29.65-599.61), and 0.96 (95% CI: 0.94-0.98) for the combination of HSPs and AFP.

Conclusion: Our analysis suggests that HSPs have potential as a biomarker for clinical use in the diagnosis of HCC, and the concurrent utilization of HSPs and AFP shows notable diagnostic effectiveness for HCC.

References

Shin E, Ryu H, Kim S, Jung H, Jang J, Lee K . The clinicopathological significance of heat shock protein 70 and glutamine synthetase expression in hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2011; 18(4):544-50. DOI: 10.1007/s00534-010-0367-0. View

Zhao S, Long M, Zhang X, Lei S, Dou W, Hu J . The diagnostic value of the combination of Golgi protein 73, glypican-3 and alpha-fetoprotein in hepatocellular carcinoma: a diagnostic meta-analysis. Ann Transl Med. 2020; 8(8):536. PMC: 7214882. DOI: 10.21037/atm.2020.02.89. View

Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S . Heat Shock Proteins and Cancer. Trends Pharmacol Sci. 2016; 38(3):226-256. DOI: 10.1016/j.tips.2016.11.009. View

Xiong J, Jiang X, Mao S, Yu X, Huang X . Heat shock protein 70 downregulation inhibits proliferation, migration and tumorigenicity in hepatocellular carcinoma cells. Oncol Lett. 2017; 14(3):2703-2708. PMC: 5588163. DOI: 10.3892/ol.2017.6531. View

Wei W, Liu M, Ning S, Wei J, Zhong J, Li J . Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma. BMC Cancer. 2020; 20(1):6. PMC: 6941289. DOI: 10.1186/s12885-019-6489-0. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Wang C, Zhang Y, Guo K, Wang N, Jin H, Liu Y . Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential. Int J Cancer. 2016; 138(8):1824-34. DOI: 10.1002/ijc.29723. View

Gruden G, Carucci P, Lolli V, Cosso L, Dellavalle E, Rolle E . Serum heat shock protein 27 levels in patients with hepatocellular carcinoma. Cell Stress Chaperones. 2012; 18(2):235-41. PMC: 3581631. DOI: 10.1007/s12192-012-0377-8. View

Fu Z, Jia B . Advances in the role of heat shock protein 90 in prostate cancer. Andrologia. 2022; 54(4):e14376. DOI: 10.1111/and.14376. View

10.

Wang X, Zhang Y, Yang N, He H, Tao X, Kou C . Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. Biomed Res Int. 2020; 2020:5087643. PMC: 7519464. DOI: 10.1155/2020/5087643. View

11.

Balogi Z, Multhoff G, Jensen T, Lloyd-Evans E, Yamashima T, Jaattela M . Hsp70 interactions with membrane lipids regulate cellular functions in health and disease. Prog Lipid Res. 2019; 74:18-30. DOI: 10.1016/j.plipres.2019.01.004. View

12.

Cauchy F, Soubrane O, Belghiti J . Liver resection for HCC: patient's selection and controversial scenarios. Best Pract Res Clin Gastroenterol. 2014; 28(5):881-96. DOI: 10.1016/j.bpg.2014.08.013. View

13.

Hartl F, Bracher A, Hayer-Hartl M . Molecular chaperones in protein folding and proteostasis. Nature. 2011; 475(7356):324-32. DOI: 10.1038/nature10317. View

14.

Lok A, Sterling R, Everhart J, Wright E, Hoefs J, Di Bisceglie A . Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2009; 138(2):493-502. PMC: 2819612. DOI: 10.1053/j.gastro.2009.10.031. View

15.

Han Y, Zhang Y, Cui L, Li Z, Feng H, Zhang Y . Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: in patients with different clinicopathologic characteristics. World J Surg Oncol. 2021; 19(1):228. PMC: 8340409. DOI: 10.1186/s12957-021-02269-4. View

16.

Fu Y, Xu X, Huang D, Cui D, Liu L, Liu J . Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial. EBioMedicine. 2017; 24:56-63. PMC: 5652007. DOI: 10.1016/j.ebiom.2017.09.007. View

17.

Ding Q, Sun Y, Zhang J, Yao Y, Huang D, Jiang Y . Utility and specificity of plasma heat shock protein 90 alpha, CEA, and CA199 as the diagnostic test in colorectal cancer liver metastasis. J Gastrointest Oncol. 2022; 13(5):2497-2504. PMC: 9660089. DOI: 10.21037/jgo-22-797. View

18.

Malek N, Schmidt S, Huber P, Manns M, Greten T . The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int. 2014; 111(7):101-6. PMC: 3957051. DOI: 10.3238/arztebl.2014.0101. View

19.

Neckers L, Blagg B, Haystead T, Trepel J, Whitesell L, Picard D . Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development. Cell Stress Chaperones. 2018; 23(4):467-482. PMC: 6045531. DOI: 10.1007/s12192-018-0877-2. View

20.

Asgharzadeh F, Moradi-Marjaneh R, Moradi Marjaneh M . The Role of Heat Shock Protein 27 in Carcinogenesis and Treatment of Colorectal Cancer. Curr Pharm Des. 2022; 28(32):2677-2685. PMC: 10249143. DOI: 10.2174/1381612828666220427140640. View